Jeenah Moon/Getty Images News
Pfizer (NYSE: PFE) has entered into a collaborative research agreement with Atavistik Bio for the discovery of new precision allosteric therapies.
The collaboration will use Atavistik’s AMPS platform to identify novel allosteric binders against two undiscovered targets selected by Pfizer (NYSE: PFE), which will also have an option to license the programs.
Financial terms of the deal were not disclosed.
